202 results about "Pyroptosis" patented technology

The invention relates to an astragaloside-loaded astragalus membranaceus exosome which is prepared by the following steps: crushing astragalus membranaceus, and filtering to obtain juice; performing multi-step differential centrifugation to obtain supernate; carrying out ultrafiltration and centrifugation, and collecting the precipitate; adding to the upper layer of a sucrose stepped gradient solution, centrifuging, and collecting part of strips; after dilution, centrifuging, discarding the supernatant, precipitating, and removing cane sugar to obtain the astragalus membranaceus exosome; the radix astragali exosome loaded with the astragaloside is obtained by mixing the radix astragali exosome with the astragaloside and carrying out ultrasonic treatment or co-incubation, and can be used for preparing medicines for specifically inhibiting cGAS / STING pathway excessive activation in cerebral ischemia reperfusion injury and downstream NLRP3 inflammasome mediated pyroptosis and preparing medicines for protecting and repairing mitochondria in the cerebral ischemia reperfusion injury. The homologous astragalus membranaceus exosome is used as a natural carrier, the blood-brain barrier is effectively overcome, and the enrichment concentration and bioavailability of astragaloside in a cerebral ischemia area are remarkably improved.

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The invention discloses a composition for enhancing cold resistance based on pyroptosis regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method of the composition for enhancing cold resistance based on pyroptosis regulation comprises the following steps: S1, respectively preparing an angelica sinensis aqueous extract and an astragalus membranaceus aqueous extract; and S2, mixing the angelica sinensis aqueous extract and the astragalus membranaceus aqueous extract according to the mass ratio of 1: (4-20) to obtain the composition for enhancing cold resistance based on pyroptosis regulation. The invention further provides a composition obtained based on the preparation method, a preparation and application. The composition provided by the invention can significantly prolong the survival time of acute cold exposure mice; the core body temperature of an acute cold exposure mouse is obviously improved, liver injury is relieved, and liver tissue cell pyroptosis pathway protein expression is regulated.

The invention discloses a drug-loaded polymer, an STAT3 inhibitor composite nanoparticle, a preparation method of the STAT3 inhibitor composite nanoparticle and application of the STAT3 inhibitor composite nanoparticle in ophthalmic drugs. The STAT3 inhibitor composite nanoparticle comprises the drug-loaded polymer, an STAT3 inhibitor loaded on the drug-loaded polymer and thermosensitive lipidosome. The drug-loaded polymer is astaxanthin macromolecules, and the astaxanthin macromolecules are prepared by the following steps: in an inert atmosphere, performing condensation polymerization on astaxanthin and HPMDA, and then performing end capping reaction by using mPEG-OH. The compound is used for treating retinal neuron progressive death and ophthalmic diseases caused by axon loss of the retinal neuron progressive death, can show good ROS response and consumption performance, inhibits necrotic apoptosis, apoptosis and pyroptosis of cells, relieves cell death performance, and can show good drug slow release performance.

The invention discloses an engineered exosome for breaking through a pyroptosis immune starting and maintaining barrier as well as a preparation method and application of the engineered exosome. The exosome is constructed by loading an immune checkpoint inhibitor into a pre-stimulated exosome, and the exosome is derived from immune cells, high-expression interferon gamma and granzyme A. The expression of the tumor cell GSDMB is up-regulated by delivering the interferon gamma through the exosome, and the exogenous granzyme A cuts the GSDMB to trigger pyroptosis; meanwhile, an immune checkpoint inhibitor blocks a PD-1 / PD-L1 pathway in situ, T cell depletion is reversed, and release of endogenous granzyme A is promoted; the pyroptosis cells release antigens to activate the T cells, the activated T cells continuously secrete granzyme A / interferon gamma to form a cascade amplification effect, and the problem of double barriers existing in the pyroptosis immune cycle of granzyme A-GSDMB is solved. The engineered exosome can improve the infiltration degree of CD8 + T cells, and is suitable for treating tumors such as liver cancer and non-small cell lung cancer.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention discloses application of cucurbitacine I in preparation of cisplatin sensitization drugs for treating ovarian cancer, and belongs to the technical field of sensitization drugs for tumor chemotherapy. CuI and CDDP have a good synergistic tumor inhibition effect on ovarian cancer, CuI may directly act on EGFR and can be combined with CDDP to significantly inhibit phosphorylation of EGFR and downstream STAT3 protein thereof, induce DNA damage and ROS accumulation, amplify a pyroptosis effect, increase release of TAAs and DAMPs, promote DC maturation and promote infiltration of CD8 + T cells and memory T cells in TIME in vivo, so that the tumor inhibition effect on ovarian cancer is improved. The expression of an inhibitory costimulatory molecule PD-1 in CD8 + T cells is reduced, the whole body immune effect is activated, and the TIME of the ovarian cancer is remarkably improved. The combined treatment strategy of CuI-CDDP controls the progress of ovarian cancer from a dual mechanism of directly inhibiting tumor cells and promoting anti-tumor immune activation.

The invention provides a diagnosis and treatment integrated nano platform as well as a preparation method and application thereof. According to the diagnosis and treatment integrated nano platform, an organic-inorganic nano hybrid is constructed through structure optimization and function integration, four modes of PTT, PDT, SDT and CDT are organically combined innovatively, and efficient synergistic treatment of GBM is achieved through real-time monitoring of photoacoustic imaging. First, a dOMV encapsulation strategy significantly improves the ability to penetrate through the blood brain barrier. Meanwhile, the IEICO-4F has a strong near-infrared absorption characteristic and has a synergistic effect with the high catalytic activity of the mesoporous platinum nanoparticles. Under the laser / ultrasonic excitation condition, the diagnosis and treatment integrated nano platform shows excellent photo-thermal conversion performance, the Fenton reaction rate can be increased, endogenous hydrogen peroxide can be continuously catalyzed to be decomposed to generate oxygen, and the tumor hypoxia state is effectively relieved. The series of reactions further enhance the generation of ROS, activate a Caspase-1 / GSDMD mediated pyroptosis pathway, finally achieve an efficient tumor inhibition effect, and successfully break through the limitation of a single treatment mode.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

The application relates to the field of biological medicine, and particularly discloses application of a sophora japonica extract in preparation of a product for improving the reproductive performance of ewes. The sophora japonica extract can effectively inhibit pyroptosis of ovarian granulosa cells by down-regulating expression of cysteine protease B, further reverses follicle atresia and ovulation disorders caused by pyroptosis, and improves the reproductive performance; animal experiments show that the sophora japonica extract can optimize the follicle development structure of ewes, inhibit overdevelopment of large follicles, and significantly improve the ovulation efficiency, thereby providing a new scheme for inhibiting pyroptosis of ovarian granulosa cells and improving the reproductive performance of livestock.

The invention discloses a marsdenia tenacissima extract as well as a preparation method and application thereof, and belongs to the technical field of medicines. The marsdenia tenacissima extract is Marsdenside A or Marsdenside C, and the structural formulas of the marsdenside A and the Marsdenside C are respectively shown as a formula I and a formula II. Marsdenside C can induce ferroptosis and inhibit liver cancer, and the liver cancer is liver cancer caused by HepG2 or Huh7 cells; the Marsdenside A induces pyroptosis to play a role in inhibiting the gastric cancer, and the gastric cancer is caused by HGC-27 or AGS cells, so that the Marsdenside C can be used for preparing the medicine for resisting the liver cancer, and the Marsdenside A can be used for preparing the medicine for resisting the gastric cancer.

The invention belongs to the technical field of organic-inorganic compounding, and aims to solve the problem of treatment of temporomandibular joint osteoarthritis (TMJOA). Magnesium-gallic acid metal organic framework (Mg-GA MOF) particles are synthesized through a hydrothermal method, hyaluronic acid is subjected to hydroformylation and double-bond modification to obtain OHAMA, and the magnesium-gallic acid metal organic framework (Mg-GA MOF) particles and the OHAMA particles are compounded to prepare the MOF-Gel composite hydrogel. The hydrogel is injectable and high in tissue retention rate, has dual effects of inhibiting pyroptosis and promoting regeneration on condylar cartilage cells, can effectively promote cartilage repair, shows a good effect in TMJOA treatment, and has a wide application prospect.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

The invention provides a method for treating autoimmune diseases mediated by regulatory T cell (Treg) programmed necrosis. Specifically, the invention provides application of an O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) accelerant, and the O-linked beta-N-acetylglucosamine glycosylation accelerant is used for preparing a medicine or a preparation for treating programmed necrosis type autoimmune diseases. It is found for the first time that when the O-GlcNAcylation promoter is used for improving the O-GlcNAcylation level of RIPK1 / 3 protein, Treg programmed necrosis can be effectively inhibited, and therefore autoimmune diseases are improved.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The application provides application of Trapidil in preparation of a drug for preventing and / or treating doxorubicin-induced organ toxicity, and belongs to the technical field of biological medicines.The application discloses that Trapidil plays an organ protection role by activating a cAMP / PKA / CREB signal axis and driving two parallel downstream effect channels: on the one hand, up-regulating an NRF2-GPX3 positive feedback loop to inhibit doxorubicin-induced myocardial cell pyroptosis and glomerular podocyte pyroptosis; and on the other hand, activating an NRF2 / HO-1 channel to inhibit myocardial cell apoptosis and glomerular podocyte apoptosis.In-vivo and in-vitro experiments prove that Trapidil can improve doxorubicin-induced cardiac dysfunction and kidney function damage, reduce histopathological damage, reduce the level of oxidative stress, inhibit the pyroptosis and apoptosis of myocardial cells and glomerular podocytes, and does not affect the antitumor effect of doxorubicin.The application provides a new drug strategy for doxorubicin chemotherapy-induced multi-organ toxicity.

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The present application belongs to the technical field of coordination chemistry and biomedical science, and provides a multifunctional iridium (III) complex, a preparation method and application thereof. The multifunctional iridium (III) complex (Mito-Ir) is composed of an iridium (III) complex cation and a coordination anion shown in the following formula. Mito-Ir can efficiently target mitochondria, and also has the abilities of phosphorescence imaging, type I and type II active oxygen generation, and photocatalytic oxidation of nicotinamide adenine dinucleotide. Under light irradiation, Mito-Ir triggers severe mitochondrial dysfunction through the above synergistic effect, and then specifically activates the caspase-3 / GSDME signaling pathway, and significantly induces pyroptosis; this pyroptosis-based cell death mechanism can effectively overcome the apoptosis tolerance of tumor cells, and is accompanied by the release of a large amount of inflammatory factors and damage-associated molecular patterns, stimulates immunogenic cell death, and activates the body's anti-tumor immune response.

The invention relates to the technical field of biological medicines, and discloses application of a ZBP1 inhibitor in preparation of a medicine for treating cognitive impairment caused by plastics. Research finds that exposure of a specific dose of nano plastic can activate a ZBP1 signal channel in an organism and promote assembly of a pan-apoptosis small body compound, so that pan-apoptosis cascade reaction with pyroptosis, apoptosis and necrosis characteristics is triggered, and finally hippocampal neuron damage, dysfunction and learning and memory ability decline are caused. Further research shows that expression of key protein of pan-apoptosis can be remarkably inhibited through local injection of the ZBP1 inhibitor to the hippocampus, cognitive function impairment induced by nano-plastics is effectively improved, and the key effect of ZBP1 serving as a core factor in the regulation and control process is defined. Based on the discovery, the ZBP1 inhibitor can be used for preparing the medicine for treating the plastic pollution related cognitive impairment, and a brand new treatment strategy is provided for clinical intervention of the diseases.

The invention relates to a caspase-1 responsive fluorescent probe based on FRET (Fluorescence Resonance Energy Transfer), a preparation method, application and a product, and belongs to the technical field of FRET fluorescent probes. The technical problem to be solved is to provide the FRET fluorescent probe capable of simultaneously carrying out in-vitro caspase-1 enzyme detection and in-vivo caspase-1 activity detection, and the specific technical scheme is that the FRET fluorescent probe with a chemical structure shown in a formula I is provided. The FRET fluorescent probe provided by the invention has short reaction time, is suitable for caspase-1 activity detection and pyroptosis imaging under a fluorescence confocal microscope, and can realize multi-scale imaging of pyroptosis in cell spheres and animal bodies.

The invention relates to a preparation method of a heavy-atom-free photosensitizer based on a BODIPY dye, the photosensitizer comprises a thiocarbamate light cage, not only can generate singlet oxygen (1O2) under red light irradiation, but also can release carbonyl sulfide (COS), and generates hydrogen sulfide (H2S) under physiological conditions through carbonic anhydrase catalysis. By reasonably adjusting the molecular structure, the singlet oxygen quantum yield and hydrogen sulfide release efficiency of the photosensitizer are remarkably improved. The method is the first case which is reported at present and can simultaneously activate and release the organic optical functional micromolecules of H2S and 1O2 through a single beam of red light. The strategy effectively solves the problem of dependence on oxygen in type II photodynamic therapy (PDT), and further effectively improves the effect of PDT hypoxic tumors. In in-vitro and in-vivo experiments, hydrogen sulfide gas and photodynamic synergic treatment trigger pyroptosis of cells, promote maturation of dendritic cells and stimulate antitumor immune response. Therefore, the invention provides a synergistic treatment strategy combining gas, photodynamic and immunotherapy, and has a remarkable effect in the aspect of hypoxic tumor treatment. The photosensitizer material disclosed by the invention is simple to prepare and low in cost, has a wide application prospect, and particularly provides a solution with huge potential for cancer treatment in the field of biomedicine.

The invention provides a method for preparing calcium-based nano particles by a reversed-phase microemulsion method, an organic calcium salt nano material and application of the organic calcium salt nano material as a nano drug, and belongs to the field of biomedical nano materials. The calcium-based nanoparticles can be formed by reacting calcium dodecyl benzene sulfonate with ammonium salt of corresponding ions or a hydroxyl-containing organic matter aqueous solution; the preparation method of the calcium-based nanoparticles has certain universality, and nano-material drugs including calcium succinate, calcium hypophosphite, calcium gluconate, calcium formate, calcium citrate and the like are successfully synthesized. The synthesis method is simple, mild in reaction condition, environment-friendly, high in repeatability, capable of realizing batch preparation and low in raw material cost. When the calcium salt nano-drug such as calcium succinate enters tumor cells through endocytosis, a large number of ions are brought into the cells, and suddenly excessive ions can cause osmotic pressure and homeostasis imbalance in the cells, activate a pyroptosis pathway of the cells and induce death of immunogenic cells.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

This invention discloses a small-molecule pyroptosis inducer for tumor cells. It utilizes an N,N-diethylimine group as an electron acceptor (A), a rhodamine scaffold as a π-conjugated system, thiophene and triphenylamine groups as the first electron donor (D1) and second electron donor (D2), respectively, and a rotatable vinyl and C-C single bond to increase intramolecular motion, forming a novel A-π-D1-D2 type small-molecule pyroptosis inducer, Rd-TTPA, with enhanced D-A structure and intramolecular motion. This small-molecule pyroptosis inducer can efficiently target tumor cell mitochondria, inducing pyroptosis through ultrasound-mediated reactive oxygen species production. It can serve as an enhanced sonodynamic deep tumor therapeutic agent guided by near-infrared II (NIR-II) fluorescence imaging.

The invention belongs to the technical field of biological medicines, and particularly relates to a membrane-coated oncolytic virus as well as a preparation method and application thereof. The oncolytic virus contains a GSDMD N-terminal expression cassette regulated and controlled by a heated shock promoter, and pyroptosis can be induced under exogenous mild thermal stimulation, so that the virus is promoted to be quickly released, and reinfection and amplification of adjacent tumor cells are realized. A bionic nano-vesicle (iNV) formed by a donor cell membrane modified by genetic engineering is used as an outer layer to coat a genetically engineered oncolytic virus (GOV) to obtain a membrane-coated oncolytic virus iNV-GOV, so that the membrane-coated oncolytic virus iNV-GOV simultaneously has immunocompatibility and active tumor recognition capability, is suitable for solid tumors such as pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC) and the like, and can be used for preparing an anti-tumor drug. And the tumor volume can be obviously reduced in mouse in-vivo model experiments.

The invention belongs to the field of tumor nano immunotherapy, and particularly relates to a nano immunotherapeutic agent cooperating with I / II type photodynamic and multiple cell death and anti-tumor application of the nano immunotherapeutic agent. The invention successfully constructs the nanoparticles (HMB) capable of targeting mitochondria and simultaneously exciting the photodynamic effects of the type I and the type II. Based on in-vitro and in-vivo experiments of a system, it is verified that ferroptosis and pyroptosis can be effectively triggered through photodynamic therapy mediated by the combination of the HMB and a ferroptosis inducer sulfasalazine. The multi-mode cell death network constructed by combining HMB with salazosulfapyridine represents a novel promising cancer treatment method, so that a novel strategy with transformation potential is provided for solid tumor treatment; and an important theoretical and practical basis is provided for deeply understanding a tumor cell death mechanism and designing a new-generation intelligent photosensitizer system according to the death mechanism.

The invention relates to application of geldanamycin in preparation of drugs for pyroptosis of cells, and relates to the technical field of biomedicine.Firstly, it is found that geldanamycin can efficiently induce pyroptosis of cells, and extracellular vesicles and drug-loading extracellular vesicles for delivering geldanamycin are further prepared; the defects of toxicity and side effects of chemotherapeutic drugs such as geldanamycin and the like during induction of pyroptosis of tumor cells are overcome, and a technology for effectively realizing tumor GSDME specific targeted therapy is provided.

The invention discloses screening of transcriptome biomarkers responsive to tanshinone IIA and application of the transcriptome biomarkers in sepsis diagnosis and treatment kits. Tanshinone IIA (TSA) inhibits an SAMSN1 gene in a targeted manner by up-regulating expression of mmu-miR-1896, so that an NRF2 / KEAP1 antioxidant pathway is activated, and GSDMD-mediated pyroptosis is inhibited, thereby reducing multi-organ injury. 10-20 mg / kg of TSA can significantly improve the alveolar structure of the LPS model and reduce inflammatory factors. A kit which is developed on the basis of the mechanism and is used for detecting the expression levels of mmu-miR-1896, SAMSN1 and NRF2-Kea1-GSDMD can be used for evaluating the curative effect.

This invention discloses a glycyrrhizic acid nanomedicine, its preparation method, and its applications, belonging to the field of biomedical nanomaterials technology. The glycyrrhizic acid nanomedicine is prepared by reacting ammonium glycyrrhizate and sodium oleate at a temperature of 15-40 °C. o Glycyrrhizate nanomedicine was prepared via a microemulsion method at temperature C. After entering tumor cells, the glycyrrhizate nanomedicine was rapidly degraded within the acidic lysosomes of the tumor cells, releasing a large amount of sodium. + The presence of glycyrrhizic acid ions and glycyrrhizic acid ions causes a surge in intracellular ion concentration and osmotic pressure, as well as the accumulation of glycyrrhizic acid within tumor cells. This induces pyroptosis in tumor cells and regulates the expression of proliferation-related proteins. Pyroptosis releases a large number of damage-associated molecular patterns (DAMPs) to trigger immune activation, while the regulation of proliferation-related protein expression inhibits tumor cell proliferation. Under the combined effect of these two factors, glycyrrhizic acid nanomedicines can not only activate the systemic anti-tumor immune response but also reduce tumor cell spread, thereby effectively inhibiting tumor growth and metastasis and enhancing the efficacy of tumor immunotherapy.